Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

Hagop M. Kantarjian, Moshe Talpaz, Susan O'Brien, Daniel Jones, Francis Giles, Guillermo Garcia-Manero, Stefan Faderl, Farhad Ravandi, Mary Beth Rios, Jianqin Shan, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

A survival benefit for imatinib mesylate versus interferon-α therapy could not be demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph)-positive chronic-phase chronic myelogenous leukemia (CML) due to the high rate of crossover (90%) from interferon-α to imatinib mesylate within a year of study entry. We compared survival in 279 patients with newly diagnosed CML treated with imatinib mesylate at our institution (2000-2004) to 650 patients treated with interferon-α (1982-1997). The complete cytogenetic response rates were 87% with imatinib mesylate and 28% with interferon-α (P < .001). The estimated 3-year survival rates were 96% with imatinib mesylate and 81% with interferon-α (P < .01). Survival rates with imatinib mesylate were significantly better than with interferon-α within each of the CML prognostic risks groups. By multivariate analysis, imatinib mesylate therapy was identified as an independent favorable prognostic factor, after accounting for the impact of pretreatment factors (hazard ratio, 0.44; P < .01). By landmark analysis at 12 months, survival within each cytogenetic response category was similar with imatinib mesylate or interferon-α, suggesting that the survival benefit of imatinib mesylate (versus interferon-α in newly diagnosed CML) is through improving cytogenetic response.

Original languageEnglish (US)
Pages (from-to)1835-1840
Number of pages6
JournalBlood
Volume108
Issue number6
DOIs
StatePublished - Sep 15 2006
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Interferons
Survival
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Survival Rate
Imatinib Mesylate
Philadelphia Chromosome
Chromosomes
Hazards
Multivariate Analysis

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. / Kantarjian, Hagop M.; Talpaz, Moshe; O'Brien, Susan; Jones, Daniel; Giles, Francis; Garcia-Manero, Guillermo; Faderl, Stefan; Ravandi, Farhad; Rios, Mary Beth; Shan, Jianqin; Cortes, Jorge.

In: Blood, Vol. 108, No. 6, 15.09.2006, p. 1835-1840.

Research output: Contribution to journalArticle

Kantarjian, HM, Talpaz, M, O'Brien, S, Jones, D, Giles, F, Garcia-Manero, G, Faderl, S, Ravandi, F, Rios, MB, Shan, J & Cortes, J 2006, 'Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia', Blood, vol. 108, no. 6, pp. 1835-1840. https://doi.org/10.1182/blood-2006-02-004325
Kantarjian, Hagop M. ; Talpaz, Moshe ; O'Brien, Susan ; Jones, Daniel ; Giles, Francis ; Garcia-Manero, Guillermo ; Faderl, Stefan ; Ravandi, Farhad ; Rios, Mary Beth ; Shan, Jianqin ; Cortes, Jorge. / Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. In: Blood. 2006 ; Vol. 108, No. 6. pp. 1835-1840.
@article{63ea0ad7ceca4277b66f95635794441a,
title = "Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia",
abstract = "A survival benefit for imatinib mesylate versus interferon-α therapy could not be demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph)-positive chronic-phase chronic myelogenous leukemia (CML) due to the high rate of crossover (90{\%}) from interferon-α to imatinib mesylate within a year of study entry. We compared survival in 279 patients with newly diagnosed CML treated with imatinib mesylate at our institution (2000-2004) to 650 patients treated with interferon-α (1982-1997). The complete cytogenetic response rates were 87{\%} with imatinib mesylate and 28{\%} with interferon-α (P < .001). The estimated 3-year survival rates were 96{\%} with imatinib mesylate and 81{\%} with interferon-α (P < .01). Survival rates with imatinib mesylate were significantly better than with interferon-α within each of the CML prognostic risks groups. By multivariate analysis, imatinib mesylate therapy was identified as an independent favorable prognostic factor, after accounting for the impact of pretreatment factors (hazard ratio, 0.44; P < .01). By landmark analysis at 12 months, survival within each cytogenetic response category was similar with imatinib mesylate or interferon-α, suggesting that the survival benefit of imatinib mesylate (versus interferon-α in newly diagnosed CML) is through improving cytogenetic response.",
author = "Kantarjian, {Hagop M.} and Moshe Talpaz and Susan O'Brien and Daniel Jones and Francis Giles and Guillermo Garcia-Manero and Stefan Faderl and Farhad Ravandi and Rios, {Mary Beth} and Jianqin Shan and Jorge Cortes",
year = "2006",
month = "9",
day = "15",
doi = "10.1182/blood-2006-02-004325",
language = "English (US)",
volume = "108",
pages = "1835--1840",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

AU - Kantarjian, Hagop M.

AU - Talpaz, Moshe

AU - O'Brien, Susan

AU - Jones, Daniel

AU - Giles, Francis

AU - Garcia-Manero, Guillermo

AU - Faderl, Stefan

AU - Ravandi, Farhad

AU - Rios, Mary Beth

AU - Shan, Jianqin

AU - Cortes, Jorge

PY - 2006/9/15

Y1 - 2006/9/15

N2 - A survival benefit for imatinib mesylate versus interferon-α therapy could not be demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph)-positive chronic-phase chronic myelogenous leukemia (CML) due to the high rate of crossover (90%) from interferon-α to imatinib mesylate within a year of study entry. We compared survival in 279 patients with newly diagnosed CML treated with imatinib mesylate at our institution (2000-2004) to 650 patients treated with interferon-α (1982-1997). The complete cytogenetic response rates were 87% with imatinib mesylate and 28% with interferon-α (P < .001). The estimated 3-year survival rates were 96% with imatinib mesylate and 81% with interferon-α (P < .01). Survival rates with imatinib mesylate were significantly better than with interferon-α within each of the CML prognostic risks groups. By multivariate analysis, imatinib mesylate therapy was identified as an independent favorable prognostic factor, after accounting for the impact of pretreatment factors (hazard ratio, 0.44; P < .01). By landmark analysis at 12 months, survival within each cytogenetic response category was similar with imatinib mesylate or interferon-α, suggesting that the survival benefit of imatinib mesylate (versus interferon-α in newly diagnosed CML) is through improving cytogenetic response.

AB - A survival benefit for imatinib mesylate versus interferon-α therapy could not be demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph)-positive chronic-phase chronic myelogenous leukemia (CML) due to the high rate of crossover (90%) from interferon-α to imatinib mesylate within a year of study entry. We compared survival in 279 patients with newly diagnosed CML treated with imatinib mesylate at our institution (2000-2004) to 650 patients treated with interferon-α (1982-1997). The complete cytogenetic response rates were 87% with imatinib mesylate and 28% with interferon-α (P < .001). The estimated 3-year survival rates were 96% with imatinib mesylate and 81% with interferon-α (P < .01). Survival rates with imatinib mesylate were significantly better than with interferon-α within each of the CML prognostic risks groups. By multivariate analysis, imatinib mesylate therapy was identified as an independent favorable prognostic factor, after accounting for the impact of pretreatment factors (hazard ratio, 0.44; P < .01). By landmark analysis at 12 months, survival within each cytogenetic response category was similar with imatinib mesylate or interferon-α, suggesting that the survival benefit of imatinib mesylate (versus interferon-α in newly diagnosed CML) is through improving cytogenetic response.

UR - http://www.scopus.com/inward/record.url?scp=33748696341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748696341&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-02-004325

DO - 10.1182/blood-2006-02-004325

M3 - Article

C2 - 16709931

AN - SCOPUS:33748696341

VL - 108

SP - 1835

EP - 1840

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -